Extra chemo tailored to tumor stage for operated pancreatic cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests whether giving different types of extra chemo (after surgery) based on the stage of your cancer can help prevent it from coming back. It's for people with pancreatic cancer who already had chemo and surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had surgery to remove pancreatic cancer, and the tumor was completely removed or had very close edges (R0 or R1).
- Before surgery, you received 3 months of chemotherapy with a drug combination called mFOLFIRINOX.
- Your cancer has not spread to other organs (no metastases) after surgery.
- You are generally healthy enough to do daily activities (ECOG 0 or 1) and your CA 19-9 level is 200 or below.
- You are at least 18 years old and have adequate blood counts and kidney function.
- You agree to use reliable birth control during and for a while after treatment (if applicable).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving treatment before surgery helps people with pancreatic cancer that can be removed. The treatment is given before the operation, and the study checks if it is safe and effective.
This trial tests a combination of chemotherapy drugs (liposomal irinotecan with fluorouracil, leucovorin, and oxaliplatin) given before and after surgery for pancreatic cancer that can be fully removed. It aims to see if this approach improves outcomes for patients with stage I or II disease.
This trial tests giving chemotherapy before any surgery to people with borderline resectable or locally advanced pancreatic cancer. The goal is to shrink the tumor, which may make surgery more successful and improve outcomes.
This trial tests a combination of a chemotherapy drug (irinotecan liposome) plus an immunotherapy drug (addebelizumab) given before surgery to people with pancreatic cancer that can be fully removed. The goal is to see if this treatment reduces the chance of the cancer coming back and improves outcomes.
This trial tests a new chemotherapy combination after surgery for pancreatic cancer to see if it helps prevent the cancer from coming back. It compares the new treatment to a standard one.
This trial uses a special gene test on fluid taken from an endoscopic ultrasound (EUS) biopsy to help choose chemotherapy before surgery for pancreas cancer. It aims to see if this approach improves outcomes by matching treatment to the tumor’s RNA pattern.
Hear when a new Resected Pancreatic Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.